News


 

 

The company finalized financial round of $4M from Pontifax, a VC leading by Eli Horovitz (Teva’s former CEO and Chairman of Teva’s board).

 

 
 on 21 june 2010 AIT was awarded as the "most promising company” in the PMWC Israel personalized medicine world conference 2010 organized by Silicon Ventures.

The decision made based on the novelty of the technology as well as the promising commercial potential.

 

 

 

 

 

 

 

 

Welcome  To  AIT

Applied Immune Technologies (AIT) is a drug development company specializing in T-Cell Receptor-Like (TCRL) antibodies that are targeted to intracellular-derived peptides for a variety of therapeutic and diagnostic applications. AIT is also focused on identification and validation of novel therapeutic targets.


Our vision is to develop highly specific 3rd generation antibodies that will revolutionize the fields of cancer, viral, and autoimmune diseases, as well as other targeted immunotherapies.

 

 






 


 


Applied Immune Technologies Ltd © All Rights Reserved


Site By Reachout
 
ארטוויז'ן | Quickyweb